Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with <i>DDX41</i> mutations-Reference-Cited by-同舟云学术

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations

Published:2024-04-10 Issue:1 Volume:29 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Wang Xin¹²,Xiao Zhijian¹²³⁴,Qin Tiejun³,Xu Zefeng¹³,Jia Yujiao⁴,Qu Shiqiang¹³,Li Bing¹²³,Pan Lijuan³,Gao Qingyan³,Jiao Meng³,Gale Robert Peter⁵

Affiliation:

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of China

2. Tianjin Institutes of Health Science, Tianjin, People’s Republic of China

3. MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of China

4. Hematologic Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People’s Republic of China

5. Department of Immunology and Inflammation, Haematology Research Centre, Imperial College London, London, UK

Funder

CAMS Initiative Fund for Medical Sciences

Haihe Laboratory of Cell Ecosystem Innovation Fund

Clinical research fund from National Clinical Research Centre for Blood Diseases

National Natural Science Funds

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2024.2338509

Reference17 articles.

1. Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms

2. Germline DDX41 mutations define a significant entity within adult MDS/AML patients

3. Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome

4. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients

5. Venetoclax and hypomethylating agent therapy in myelodysplastic syndromes: Big picture perspective